These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 18605514)

  • 1. A journey to continence: a case study of overactive bladder syndrome.
    Spilde NL
    Urol Nurs; 2008 Jun; 28(3):209-12. PubMed ID: 18605514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of urinary incontinence in older persons.
    Zarowitz BJ; Ouslander JG
    Geriatr Nurs; 2006; 27(5):265-70. PubMed ID: 17045125
    [No Abstract]   [Full Text] [Related]  

  • 3. Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q).
    Margolis MK; Fox KM; Cerulli A; Ariely R; Kahler KH; Coyne KS
    Neurourol Urodyn; 2009; 28(5):416-22. PubMed ID: 19030182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pediatric voiding dysfunction: a case study.
    Ellsworth P; Caldamone A
    Urol Nurs; 2008 Aug; 28(4):259-61; quiz 262. PubMed ID: 18771158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relevance of health-related quality of life outcomes with darifenacin.
    Abrams P; Kelleher C; Huels J; Quebe-Fehling E; Omar MA; Steel M
    BJU Int; 2008 Jul; 102(2):208-13. PubMed ID: 18325056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overactive bladder: an update.
    Hashim H; Abrams P
    Curr Opin Urol; 2007 Jul; 17(4):231-6. PubMed ID: 17558264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient experience with darifenacin - results of a short-term community-based survey in managing overactive bladder.
    Green L; Kerney D
    Curr Med Res Opin; 2011 Feb; 27(2):431-7. PubMed ID: 21194391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relative importance of health related quality of life and prescription insurance coverage in the decision to pharmacologically manage symptoms of overactive bladder.
    Harpe SE; Szeinbach SL; Caswell RJ; Corey R; McAuley JW
    J Urol; 2007 Dec; 178(6):2532-6; discussion 2536. PubMed ID: 17937937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study.
    Dwyer P; Kelleher C; Young J; Haab F; Lheritier K; Ariely R; Ebinger U
    Neurourol Urodyn; 2008; 27(6):540-7. PubMed ID: 18663723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial.
    Chapple C; DuBeau C; Ebinger U; Rekeda L; Viegas A
    Curr Med Res Opin; 2007 Oct; 23(10):2347-58. PubMed ID: 17706004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.
    Tseng LH; Wang AC; Chang YL; Soong YK; Lloyd LK; Ko YJ
    Neurourol Urodyn; 2009; 28(1):47-51. PubMed ID: 19089890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interstitial granulomatous dermatitis associated with darifenacin.
    Mason HR; Swanson JK; Ho J; Patton TJ
    J Drugs Dermatol; 2008 Sep; 7(9):895-7. PubMed ID: 19112808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of overactive bladder in a difficult-to-treat patient with a transdermal formulation of oxybutynin.
    Saltzstein L
    Urol Nurs; 2005 Aug; 25(4):260-2. PubMed ID: 16225342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overactive bladder syndrome in the older woman: conservative treatment.
    Stewart E
    Br J Community Nurs; 2009 Nov; 14(11):466, 468, 470-3. PubMed ID: 20166470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary incontinence in women.
    Wilkinson E
    Nurs Times; 2006 Nov 28-Dec 4; 102(48):23-4. PubMed ID: 17193773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The MATRIX study: assessment of health-related quality of life in adults with the use of transdermal oxybutynin.
    Newman DK
    Director; 2008; 16(1):22-5. PubMed ID: 19343871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective assessment of overactive bladder symptoms in a cohort of elderly women who underwent transvaginal surgery for advanced pelvic organ prolapse.
    Foster RT; Barber MD; Parasio MF; Walters MD; Weidner AC; Amundsen CL
    Am J Obstet Gynecol; 2007 Jul; 197(1):82.e1-4. PubMed ID: 17618768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
    Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M;
    BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solifenacin and darifenacin for overactive bladder.
    Obstet Gynecol; 2005 Aug; 106(2):401-2. PubMed ID: 16055596
    [No Abstract]   [Full Text] [Related]  

  • 20. [The recommendations of the Polish Gynecologic Society regarding the use of darifenacin, selective muscarinic antagonists in the treatment of overactive bladder].
    Ginekol Pol; 2007 Oct; 78(10):815-20. PubMed ID: 18200976
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.